Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Lymphoma, B-Cell × Dexamethasone × Clear all

Phase

Phase 1 3 Phase 1/2 2 Phase EARLY_PHASE1 1 Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 142 Precursor Cell Lymphoblastic Leukemia-Lymphoma 31 Recurrence 23 Vomiting 22 Leukemia 22 Neoplasms, Plasma Cell 17 Neoplasms 16 Lymphoma 16 Nausea 12 Burkitt Lymphoma 9 Prostatic Neoplasms 8 Immunoglobulin Light-chain Amyloidosis 7 Carcinoma, Non-Small-Cell Lung 6 Lung Neoplasms 5 Hodgkin Disease 5 Ovarian Neoplasms 4 Neoplasm Metastasis 4 Lymphoma, Follicular 4 Breast Neoplasms 4 Uterine Cervical Neoplasms 3 Small Cell Lung Carcinoma 3 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Paraproteinemias 3 Lymphoma, Non-Hodgkin 3 Lymphoma, Large B-Cell, Diffuse 3 Fallopian Tube Neoplasms 3 Carcinoma, Hepatocellular 3 Smoldering Multiple Myeloma 2 Plasmacytoma 2

Interventions

Rituximab 12 pirtobrutinib 5 ibrutinib 4 Vincristine 3 Doxorubicin 3 Cytarabine 3 zanubrutinib 2 Prednisone 2 Etoposide 2 Cyclophosphamide 2 Bendamustine Hydrochloride 2 venetoclax 1 tositumomab I-131 1 idelalisib 1 ibritumomab tiuxetan 1 etoposide phosphate 1 entecavir 1 cirmtuzumab 1 axicabtagene ciloleucel 1 acalabrutinib 1 VAP-cyclo protocol 1 Tenofovir 1 Radiotherapy 1 Methotrexate 1 Melphalan 1 Ifosfamide 1 Gemcitabine 1 Drug Therapy 1 Dexamethasone 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06230224 2026-02-06

OLYMPIA-4

Regeneron Pharmaceuticals

Phase 3 Recruiting

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡